Videos

Experts offer their clinical experience discussing how they utilize off label drugs in the treatment of fibromyalgia (FM).

Experts offer their clinical experience with nonsteroidal anti-inflammatory drugs (NSAID) in the treatment of fibromyalgia (FM).

Experts discuss their therapeutic approach and key agents utilized in the treatment of fibromyalgia (FM).

Albert Roy, president of the Lupus Research Alliance, elaborates on recent initiatives designed to address the underrepresentation of minorities in lupus research.

Albert Roy, president of the Lupus Research Alliance, discusses the efforts his team are making to combat the underrepresentation of minorities in clinical trials as well as the scientific research profession.

Experts discuss treatment options for fibromyalgia (FM) and how they utilize integrative care with patients.

Experts discuss which providers often diagnose fibromyalgia (FM) and how the burden of care has changed in recent years.

Experts discuss common comorbidities for patients with fibromyalgia (FM).

Experts offer clinical experience on why fibromyalgia (FM) is challenging to diagnose and how they rule out other chronic pain disorders.

At the 12-month mark, response rate in patients with uncontrolled gout was significantly higher in those treated with pegloticase and concomitant methotrexate when compared with placebo.

Experts offer their clinical advice on what factors, outside of clinical therapies, may mitigate symptoms of fibromyalgia (FM).

Experts discuss the common characteristics of fibromyalgia (FM) and related symptoms.

Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.

Carola Vinuesa, MD, PhD, recipient of the Lupus Research Alliance Lupus Insight Prize, discovered a mutation in a specific human gene that causes systemic lupus erythematosus.

Experts discuss known risk factors of fibromyalgia (FM).

Experts discuss the pathophysiology of fibromyalgia (FM) and how it relates to other chronic pain diseases.

Experts offer their clinical experience on why fibromyalgia (FM) is often misunderstood by patients and practitioners.

Wendy Wright, DNP, Kostas Botsoglou, MD, Daniel Clauw, MD, and Benjamin Natelson, MD, present an overview of symptoms and characteristics of fibromyalgia (FM).

Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.

The study stresses the need for better communication with patients and the impact of stress on both the rheumatic disease and mental health.

Results emphasized the challenges faced in accessing care and the impact on mental health for patients with rheumatic diseases.

Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.

An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.

An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.

Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.

Janssen's efforts are accompanied by extensive data generation in patients of color and the creation of a diverse workforce.

Janssen aims to address health inequities and promote culturally competent care.

Dr David Hudesman, Dr Jordan Axelrad, and Dr Jose Scher discuss strategies for managing coexisting inflammatory bowel disease and psoriatic arthritis and highlight the importance of a multidisciplinary approach to providing comprehensive care.

Results of a recent study found that fibromyalgia may be more common among individuals with opioid use disorder, and that treating fibromyalgia may be beneficial for treating opioid use disorder.

Patients with fibromyalgia were more likely to report that pain caused them to continue using opioids, to increase the amount of opioids they used over time, and to delay getting addiction treatment.